MedTrace Logo

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

NCT00981903 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 131

Last updated 2017-07-06

No results posted yet for this study

Summary

In this study the investigators will determine the safety and effectiveness of Tinzaparin in preventing blood clots for up to 12 months of treatment.

Conditions

  • Venous Thromboembolism
  • Cancer

Interventions

DRUG

Tinzaparin sodium

Subcutaneous injection 175 U/Kg/day

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • University of Southern California

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2012-10-31
Completion
2015-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00981903 on ClinicalTrials.gov